Literature DB >> 15695164

Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.

Signe F Bomholt1, Jens D Mikkelsen, Gordon Blackburn-Munro.   

Abstract

The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain. None of the drugs (all 3-30 mg/kg, i.p.) affected acute nociceptive responses as measured in the tail flick test. In the hot plate test, duloxetine and mirtazapine significantly increased (P<0.05) the nociceptive response latency, whereas amitriptyline and citalopram were ineffective. In the formalin test, duloxetine and citalopram significantly attenuated, whereas amitriptyline and mirtazapine increased, second phase flinching behaviour (all P<0.05). However, amitriptyline and mirtazapine reduced second phase licking behaviour. In the chronic constriction injury model of neuropathic pain, thermal hyperalgesia of the injured hindpaw was significantly attenuated by all four drugs (P<0.05); only amitriptyline and duloxetine fully reversed thermal hypersensitivity. None of the drugs tested attenuated mechanical allodynia. In contrast amitriptyline, duloxetine and mirtazapine significantly reduced mechanical hyperalgesia (P<0.05); citalopram was ineffective. No drug-related effects on motor performance in the rotarod test were observed. These results (a) highlight the difficulty in correlating antinociceptive effects of drugs from different antidepressant classes across a range of animal pain models and (b) suggest that antidepressants that variously affect both noradrenaline and serotonin levels have more potent and efficacious antinociceptive effects than SSRIs (as exemplified by citalopram), against a range of pain-like behaviours in an animal model of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695164     DOI: 10.1016/j.neuropharm.2004.09.012

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  42 in total

1.  WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.

Authors:  G T Whiteside; J M Dwyer; J E Harrison; C E Beyer; T Cummons; L Manzino; L Mark; G H Johnston; B W Strassle; A Adedoyin; P Lu; M J Piesla; C M Pulicicchio; J C L Erve; B J Platt; Z A Hughes; K E Rogers; D C Deecher; E J Trybulski; J D Kennedy; P Zhang; L Leventhal
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 2.  Use of psychopharmacological agents for functional gastrointestinal disorders.

Authors:  R E Clouse; P J Lustman
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 3.  Antidepressants as analgesics.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  New index of pain triggered by spinal activation of voltage-dependent sodium channels.

Authors:  Ryugo Enomoto; Mina Tsukamoto; Yukinori Shimoshige; Toshiaki Aoki; Nobuya Matsuoka
Journal:  J Anesth       Date:  2013-06-13       Impact factor: 2.078

5.  Treatment of Functional GI Disorders With Psychotropic Medicines: A Review of Evidence With a Practical Approach.

Authors:  Syed I M Thiwan; Douglas A Drossman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-09

6.  Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion.

Authors:  Cristiano R Jesse; Ethel A Wilhelm; Cristina W Nogueira
Journal:  Psychopharmacology (Berl)       Date:  2010-08-06       Impact factor: 4.530

7.  Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain.

Authors:  Louise H Pedersen; Alexander N Nielsen; Gordon Blackburn-Munro
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

8.  Multiplicative interactions to enhance gabapentin to treat neuropathic pain.

Authors:  Ken-Ichiro Hayashida; James C Eisenach
Journal:  Eur J Pharmacol       Date:  2008-09-17       Impact factor: 4.432

9.  Rats with chronic post-ischemia pain exhibit an analgesic sensitivity profile similar to human patients with complex regional pain syndrome--type I.

Authors:  Magali Millecamps; Terence J Coderre
Journal:  Eur J Pharmacol       Date:  2008-01-26       Impact factor: 4.432

10.  Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats.

Authors:  Marisa B Rosenberg; F Ivy Carroll; S Stevens Negus
Journal:  J Pain       Date:  2013-01-16       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.